In my view, IonQ, Inc. (IONQ) is making the strongest commercial case for quantum computing among pure-play public companies right now. Although I am cautiously bullish on IonQ’s long-term opportunity, I believe the stock’s current valuation assumes a high level of future execution that the financial profile still needs time to support.
Claim 55% Off TipRanks
Explore QBTX for 2X leverage on QBTSIonQ is a quantum computing company that builds and operates trapped-ion quantum systems, delivering compute access through cloud platforms and direct hardware deployments. Q1 2026 was the company’s fourth consecutive quarter of record-breaking results, with GAAP revenue reaching $64.7 million, up 755% year-over-year, and remaining performance obligations (RPOs) surging 554% to $470 million.
From Research Story to Commercial Platform
The most important shift in the IonQ narrative over the past 12 months has to be what is driving its revenue growth. According to management’s commentary during the Q1 2026 earnings call, 60% of revenue now comes from commercial customers, and 35% from international markets, with IonQ selling into more than 30 countries. More than 35% of revenue comes from customers deploying multiple solutions across computing, networking, sensing, and security portfolios, which tells me this is not a single-product relationship with a handful of accounts.
If we look at the contract wins, the trend is even more obvious. For one, the company recently won a $39 million Space Development Agency HALO contract and was selected for DARPA’s Heterogeneous Architectures for Quantum (HARQ) program. Those are two major long-term programs that show that IonQ is becoming a serious player in federal government contracting, along with its commercial traction.
Acquisitions Are Crucial to the Topline Expansion
Then we have the pending SkyWater Technology (SKYT) acquisition, which shareholders have already approved. When the deal closes, it will give IonQ direct access to a U.S.-based semiconductor foundry and advanced packaging capabilities. That is a major advantage that allows the company to reduce its manufacturing dependency and accelerate the path to fault-tolerant systems at scale.
The other thing I want to flag is the contribution of the acquisition to the headline growth rate. Management is projecting 100% year-over-year organic growth for 2026, and that tells me that, even stripping out inorganic contributions, the underlying business is compounding at a rate most technology companies at any stage would envy. That is an important distinction for investors trying to assess the quality of the revenue.
The Financials Require Careful Reading
If you only looked at IonQ’s bottom line over the previous two quarters with no context or prior knowledge of the company, you’d think it was an immensely profitable business. After all, it recorded GAAP net income of $805.4 million in Q1 2026 and $754 million in Q4 2025.
Yet that’s not the case: it is still a loss-making machine that recorded positive net income only because of a $1.1 billion non-cash warrant valuation adjustment. Its adjusted earnings per share (EPS) was negative $0.34, and adjusted EBITDA loss came in at $96.75 million for the quarter, with management guiding a full-year adjusted EBITDA loss of $310 million to $330 million. The company’s operating cash flow was negative $151 million in Q1 alone.
Fortunately, the balance sheet provides a meaningful cushion against that burn. IonQ ended the quarter with $3.1 billion in cash, giving the company several years of runway to execute against its roadmap without worrying about financing in the near term. I cannot overstate how important the cash buffer is, given that it is working in a sector where milestones frequently slip. Management raised full-year 2026 revenue guidance to $260–$270 million and guided Q2 revenue of $65–$68 million, both of which suggest the commercial momentum is not a one-quarter event.
Valuation and Peers
IonQ currently trades at approximately $49 per share, giving it a market cap of roughly $19 billion. Its 12-month trailing (TTM) P/S multiple is approximately 103x, compared with a technology-sector median of 3x–5x. Even on a forward basis, if we apply the midpoint of full-year guidance of $265 million, the stock trades at roughly 70x forward sales. That is a figure that assumes the market is buying IonQ’s entire trajectory over the next five to seven years, which is a very long time in the quantum computing industry.
The most useful peer comparison we can use here is D-Wave Quantum (QBTS), which reported Q1 2026 revenue of $2.86 million against IonQ’s $64.7 million. QBTS’s P/S ratio is so much higher, too, at 558x, but the value proposition here is fundamentally different from IonQ. Unlike IonQ’s smooth GAAP execution, D-Wave’s backward-looking multiple is distorted by strict revenue recognition timelines; the company actually booked a record $33.4 million in new bookings in Q1 alone, which will be recognized as revenue over future periods and has not yet hit the income statement.
Rigetti Computing (RGTI) is the other meaningful public comparable, and it similarly lags IonQ in every revenue and valuation metric. Clearly, IonQ is the leader here, both in terms of revenue and structural commercialization. In my view, the company is creating a solid moat, and the valuation premium will hold for the foreseeable future.
What Is Wall Street Saying?
Turning to Wall Street, IonQ has a Strong Buy consensus rating based on 9 Buys and three Holds assigned in the last three months. At $60.86, the average IonQ price target implies 25.65% upside potential.
I think the valuation target range reflects my cautious bullishness: the lowest target is $35, and the highest is $85. Clearly, valuing a company growing this fast in a sector with no established comparable set is far from straightforward.
In Conclusion
IonQ is one of the few companies that has managed to move the quantum computing story from speculative to commercially credible, and Q1 2026 is the clearest evidence of that yet. The RPO growth, the customer diversification, the government contract wins, and the 100% organic growth projection are all genuine positives that I cannot dismiss.
What I cannot dismiss is a TTM P/S ratio of roughly 103x on a business guiding for $310–$330 million in adjusted EBITDA losses this year. I like its long-term outlook, but I believe there’s a better entry point for the stock than $49 per share.